Table 2.
Univariable analysis of risk factors for multiresistant Acetinobacter baumannii acquisition during ICU hospitalization
| Variable | Univariable analysis | |||
|---|---|---|---|---|
| Patients with A. Baumannii acquisition (n = 32) | Patients without A. baumannii acquisition (n = 172) | OR (95% CI) | P value | |
| Age, median [IQR] | 51 (32-69) | 63 (40.25-72) | 0.98 (0.97-1.003) | 0.10 |
| Males n (%) | 24 (75) | 108 (63) | 1.78 (0.75-4.19) | 0.19 |
| APACHE II, median [IQR] | 17 (13-22) | 17 (13-22.75) | 0.98 (0.93-1.03) | 0.39 |
| SAPS II, median [IQR] | 40 (27.2-52) | 41 (29-53) | 0.99 (0.97-1.01) | 0.31 |
| ODIN, median [IQR] | 2 (1.25-3) | 2 (1-3) | 1.03 (0.76-1.38) | 0.86 |
| Mc Cabe n (%) | ||||
| 0-1 | 25 (75) | 109 (63) | 2.06 (0.85-5.05) | 0.11 |
| 2-3 | 7 (25) | 63 (37) | ||
| Reason for ICU admission n (%) | ||||
| Medical reason for ICU admission | 28 (88) | 110 (64) | 3.85 (1.29-11.48) | 0.016 |
| Surgery before ICU admission | 4 (12) | 62 (36) | ||
| Trauma | 11 (34) | 33 (19) | 2.2 (0.97-5.02) | 0.06 |
| Infection at ICU admission | 6 (19) | 23 (20) | 1.49 (0.57-4.02) | 0.43 |
| Main reason for ICU admission n (%) | ||||
| Other | 6 (18.7) | 42 (24.4) | ||
| Acute respiratory failure | 9 (28) | 46 (27) | 0.73 (0.24-2.22) | 0.58 |
| Neurologic disorder | 15 (47) | 66 (38) | 0.63 (0.22-1.75) | 0.37 |
| Hemodynamic disorder | 2 (6) | 18 (15) | 1.28 (0.23-6.99) | 0.77 |
| ICU days before acquisition, median [IQR] | 11.5 (9-18.75) | 5 (3-10) | 1.03 (1.01-1.06) | 0.025 |
| Antibiotic use before acquisition n (%) | 32 (100) | 127 (74) | 10.98 (1.46-82.8) | 0.02 |
| Days of antibiotics median [IQR] | 7 (5-9.75) | 3 (0-5) | 1.28 (1.15-1.42) | < 0.001 |
| Mechanical ventilation before acquisition n (%) | 32 (100) | 152 (88) | 4.08 (0.53-31.5) | 0.18 |
| Days of mechanical ventilation, median [IQR] | 11.5 (8.25-16) | 4 (2-8) | 1.09 (1.05-1.14) | < 0.001 |
| CVC in the ICU before acquisition n (%) | 26 (81) | 152 (88) | 0.57 (0.209-1.554) | 0.27 |
| Days of CVC, median [IQR] | 12 (9-15.7) | 6 (3-10) | 1.07 (1.03-1.12) | 0.001 |
| Propofol use before acquisition n (%) | 12 (38) | 131 (76) | 0.19 (0.09-0.42) | < 0.001 |
| Days of propofol, median [IQR] | 5 (3.75-7) | 2 (1-3) | 1.20 (1.07-1.36) | 0.003 |
| Arterial catheter before acquisition n (%) | 20 (63) | 154 (89.5) | 2.06 (0.95-4.69) | 0.07 |
| Days of arterial catheter, median [IQR] | 11 (8-14.7) | 6 (3-9) | 1.07 (1.02-1.13) | 0.003 |
| Enteral feeding catheter before acquisition n (%) | 31 (97) | 155 (90) | 1.48 (0.64-3.39) | 0.36 |
| Days of enteral feeding tube, median [IQR] | 12 (9.2-19) | 4 (3-9) | 1.07 (1.04-1.10) | < 0.001 |
| Urinary catheter before acquisition n (%) | 32 (100) | 165 (96) | 2.53 (0.32-20.08) | 0.38 |
| Days of urinary tract catheterization, median [IQR] | 12.5 (9-18.25) | 6 (3-11) | 1.07 (1.04-1.10) | < 0.001 |
APACHE II, Acute Physiologic And Chronic Health Evaluation; CI, confidence interval; CVC, central venous catheter; ICU, intensive care unit; IQR, interquartile range; ODIN, Organ Dysfunctions and/or Infection; OR, odds ratio; other, postsurgery follow-up, trauma, cancer, and immunodeficiency; SAPS II, Simplified Acute Physiology Score II.